Journal article · 2024 · Open access

Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation

Julia Wicherski, Britta Haenisch

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 67(2), 149–154 · Published 12 January 2024 · DOI 10.1007/s00103-023-03830-0

Open PDFView at the publisherCite this paper

In brief

“Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation” is a 2024 journal article by Julia Wicherski and Britta Haenisch, published in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. OpenAlex counts 1 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
0.23
References
15
Authors
2

Abstract

Drug regulation is a system to support and protect public health. Drugs with market access must be effective, safe and of high quality. Therefore, drug regulatory decision-making by the competent authorities is made on a scientific basis. Real-world evidence (RWE) from real-world data (RWD) has so far predominantly been taken into account in a supportive manner in drug regulatory decision-making with regard to drug safety after marketing authorisation. The extensive potential of RWE for regulatory decision-making processes along the entire product life cycle has been increasingly used and further examined in recent years.This article provides an overview of current applications of RWE in drug regulatory decision-making processes. The potentials of RWE along with the hurdles to be addressed are described and examples of current projects on RWE research for drug regulation are given. The work is based on current international literature as well as examples from international and European initiatives and regulatory practice, which aim to support an increased use of RWD/RWE in regulatory decision-making processes. In order to be able to utilise the potential of RWE even more in the future, it is important to make relevant RWD sources more readily available through research projects and initiatives, to further develop evaluative methods and to establish the significance of RWE.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wicherski, J., & Haenisch, B. (2024). Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 67(2), 149–154. https://doi.org/10.1007/s00103-023-03830-0

MLA 9

Wicherski, Julia, and Britta Haenisch. “Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation.” Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, vol. 67, no. 2, 2024, pp. 149–154. https://doi.org/10.1007/s00103-023-03830-0.

Chicago

Wicherski, Julia and Britta Haenisch. 2024. “Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation.” Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 67 (2): 149–154. https://doi.org/10.1007/s00103-023-03830-0.

Harvard

Wicherski, J. and Haenisch, B. (2024) ‘Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation’, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 67(2), pp. 149–154. doi:10.1007/s00103-023-03830-0.

IEEE

J. Wicherski and B. Haenisch, “Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation,” Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, vol. 67, no. 2, pp. 149–154, 2024, doi: 10.1007/s00103-023-03830-0.

BibTeX

@article{wicherski2024anwendung,
  title     = {{Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation}},
  author    = {Wicherski, Julia and Haenisch, Britta},
  journal   = {Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz},
  year      = {2024},
  volume    = {67},
  number    = {2},
  pages     = {149--154},
  doi       = {10.1007/s00103-023-03830-0},
  url       = {https://doi.org/10.1007/s00103-023-03830-0}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy

  • real-world evidence
  • real-world data
  • drug regulation
  • regulatory decision-making
  • product life cycle
  • drug approval

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Wicherski, J., & Haenisch, B. (2024). Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 67(2), 149–154. https://doi.org/10.1007/s00103-023-03830-0

How many times has this paper been cited?

1 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz: sign in and open the PDF from this page.

Who wrote this paper?

Julia Wicherski, Britta Haenisch.

What is the DOI of this paper?

10.1007/s00103-023-03830-0, permanently at https://doi.org/10.1007/s00103-023-03830-0. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.